Gemedy Inc - 02139 Cambridge, MA

Business Name: Gemedy Inc
Categorized In: Research and Development Laboratories
Address: 485 Msschstts Avenue # 300, Cambridge, MA 02139
Phone Number: (617) 909-9206
Contact Person: Timothy Sullivan
Website Address: gemedy.com
NAICS Code: 541712
SIC Code: 8731
Business Type: B2B (Business to Business)
Founding Year: 2011
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): $100.000 to $499.999
Share This Business:
Similar Businesses: Ambri Inc - Cambridge, MA 02139
Simba Medical LLC - Cambridge, MA 02139
Sunpoint Technologies Inc - Cambridge, MA 02139
Aramark - Cambridge, MA 02139
Twin Lights Bioscience Inc - Cambridge, MA 02139
Good Start Genetics Inc - Cambridge, MA 02139
Hybrid Silica Technologies Inc - Cambridge, MA 02139
Unison Technologies LLC - Cambridge, MA 02139
H3 Biomedicine Inc - Cambridge, MA 02139
Axios Biosciences LLC - Cambridge, MA 02139
Seaside Therapeutics LLC - Cambridge, MA 02139
Epieye Technologies - Cambridge, MA 02139
Realtime Technologies Limited - Cambridge, MA 02139
Srinivas Tejaswinhi - Cambridge, MA 02139
Axia Systems Technology Inc - Cambridge, MA 02139
Kozmoz LLC - Cambridge, MA 02139
Ektek LLC - Cambridge, MA 02139
Q-State Biosciences Inc - Cambridge, MA 02139
Oravax Inc - Cambridge, MA 02139
One Cell - Cambridge, MA 02139

Gemedy Inc provides professional Research and Development Laboratories from its single location at the coordinates 42.364251,-71.101487.

The company offers B2B variables under the SIC code 8731 and NAICS code 541712, while making an annual revenue of $100.000 to $499.999 and hiring a total of 1 to 4 employees.

Founded in 2011, the company can now be visited at 485 Msschstts Avenue # 300, Cambridge, Massachusetts 02139 or contacted through representative Timothy Sullivan at (617) 909-9206.

For frequently asked questions and further inquiries about professional Research and Development Laboratories, get to know more about Gemedy Inc through its company website at gemedy.com. Engage with this business on its social media platforms through on Twitter and on Facebook.